USA flag logo/image

An Official Website of the United States Government

Development of Sulfamoylbenzamide Derivatives as Antiviral Agents against HBV…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43AI098200
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA11-096
Small Business Information
ENANTIGEN THERAPEUTICS, INC.
3805 OLD EASTON RD DOYLESTOWN, PA 18902-8400
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Development of Sulfamoylbenzamide Derivatives as Antiviral Agents against HBV Inf
Agency: HHS
Contract: 1R43AI098200-01A1
Award Amount: $300,000.00
 

Abstract:

DESCRIPTION (provided by applicant): This is a proposal to develop newly discovered sulfamoylbenzamide derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as inhibitors of HBV pregenomic (pg) RNA encapsidation, a critical step in the life cycle of HBV. PgRNA is the template for reverse transcriptional replication of HBV DNA, and its encapsidation into nucleocapsid with viral DNA polymerase is essential for the subsequent viral DNA synthesis. Distinct from the mechanism of the currently FDA-approved antiviral nucleos(t)ide analogues that inhibit HBV DNA polymerase, pgRNA assembly into nucleocapsids represents a novel therapeutic target and should complement the current antiviral medications. Through an extensive structure-activity-relationship (SAR) study of 591 sulfamoylbenzamide derivatives, we have already obtained compounds with sub-micromolar antiviral activity, with the best being DVR-23 (EC50 = 280 nM, EC90 = 860nM). In this Phase I project, we propose to further optimize the sulfonamide moiety of the current compounds to identify leads with superior antiviral, pharmacokinetic and toxicology profiles, and to test their antiviral efficacy in the HBV transgenic mouse model in vivo PUBLIC HEALTH RELEVANCE: This is a proposal to develop newly discovered inhibitors of hepatitis B virus (HBV), referred to as sulfamoylbenzamide derivatives, into a drug for treatment of chronic hepatitis B. These compounds function by interfering with packaging of the template for viral DNA synthesis, pregenomic RNA, constituting a mechanism which is distinct from the currently FDA-approved anti-HBV medications. Hence, the drug may be of use by itself or in combination with current medications to achieve extended clinical benefits.

Principal Investigator:

Xiaodong Xu
215-589-6350
michaelxu@enantigen.com

Business Contact:

Xiaodong M. Xu
215-589-6350
MichaelXu@enantigen.com
Small Business Information at Submission:

ENANTIGEN THERAPEUTICS, INC.
3805 OLD EASTON RD DOYLESTOWN, PA 18902-8400

EIN/Tax ID: 126156958
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No